查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466395

感染疾病體外診斷市場：按產品、技術、適應症和最終用戶分類 - 全球預測 2024-2030 年

Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年感染疾病體外診斷市場規模為490.6億美元，2024年達525.1億美元，預計2030年將達799.5億美元，複合年成長率為7.22%。

感染疾病體外診斷市場包括用於從血液、尿液和咽拭子等人體樣本中檢測和識別感染疾病的設備、耗材和服務。這些診斷劑具有廣泛的用途，包括人類免疫力缺乏病毒（HIV）、肝炎、結核病、性行為感染（STI）和呼吸道感染疾病。這些檢測對於早期發現、疾病監測、流行病學和感染疾病控制至關重要。感染疾病體外診斷市場的成長受到以下因素的影響：全球感染疾病流行率不斷上升、對早期檢測和預防重要性的認知和教育不斷提高、醫療支出和醫療基礎設施投資的增加。然而，嚴格的法規環境、缺乏基礎設施和訓練有素的人員以及先進技術的高成本是市場成長的主要障礙。此外，用於快速現場診斷的就地檢驗套件的開發以及人工智慧和機器學習演算法的整合以提高診斷準確性和預測分析為馬蘇感染疾病提供了顯著的成長機會。

主要市場統計
基準年[2023] 490.6億美元
預測年份 [2024] 525.1億美元
預測年份 [2030] 799.5億美元
複合年成長率（%） 7.22%

產品傳染性病原體檢測對先進試劑的需求不斷成長

感染疾病診斷需要複雜且專門的設備來檢測臨床樣本中病原體的存在。這些設備的範圍從簡單的就地檢驗套件到複雜的檢測設備，例如 PCR 機、免疫測量分析儀和下一代定序儀。不同的醫療保健環境有不同的設備需求，參考實驗室偏好高通量系統以提高效率和自動化，而照護現場環境則需要攜帶式、易於使用的設備。試劑是感染疾病診斷的重要消耗品，由化學物質和生物物質組成，用於檢測病原體特異性標記物的存在。試劑包括引子、探針、抗體、酵素和其他測試所需的物品。試劑的需求取決於所進行的測試量和可測試病原體的多樣性。因此，實驗室通常更喜歡能夠為多個測試設備平台提供多種試劑的供應商。感染疾病診斷軟體領域包括資料分析、判讀軟體、資訊管理系統等，對於提高診斷業務效率至關重要。軟體偏好基於方便用戶使用的介面、強大的資料管理功能、與其他醫院系統的互通性以及符合 HIPAA 等監管標準。

技術：更多採用分子診斷技術來快速檢測和量化病毒量，例如愛滋病毒和肝炎感染

免疫化學（免疫測量）是感染疾病的重要技術，利用免疫反應（抗體、抗原）來檢測和定量樣本中的特定生物標記。這包括 ELISA（酵素結合免疫吸附檢測法）、橫向流動化驗和西方印漬術等測試。微生物學是識別感染疾病的基本方法，通常透過採集樣本並使用生化和表現型分析來分離和識別病原體。微生物學對於抗藥性檢測和了解感染疾病的流行病學至關重要。需要有關病原體的抗生素敏感性的資訊來指南標靶治療。分子診斷分析核酸以高靈敏度和特異性辨識傳染原。常見技術包括聚合酵素鏈鎖反應、逆轉錄 PCR 和次世代定序儀。

區域洞察

由於先進的醫療基礎設施、感染疾病的高發病率以及主要企業的強大影響力，美洲佔據了感染疾病體外診斷市場的大部分。最近的趨勢包括採用分子診斷 (MDx)、即時護理 (PoC) 測試以及增加對個人化醫療的投資。歐盟國家擁有不同的醫療保健系統和法規，但共同表現出對高品質體外診斷的強烈需求。歐盟客戶重視測試的準確性和可靠性，也必須遵守嚴格的歐盟法規。中東和非洲地區市場多樣，發展程度各異。在中東國家，對尖端醫療保健解決方案（包括最新的體外診斷）的需求很高。波灣合作理事會(GCC) 國家對醫療基礎設施的投資非常巨大。同時，在非洲市場，感染疾病傳播和獲得醫療服務有限等挑戰需要具有成本效益和強力的測試。國際舉措通常會推動投資和創新，重點是擴大診斷的覆蓋範圍和發展當地的專業知識。

亞太地區感染疾病體外診斷市場正在快速成長。中國龐大的人口和不斷上漲的醫療成本正在推動市場成長，政府對改善醫療基礎設施的大力支持。憑藉先進的技術，日本專注於高階自動化診斷解決方案，是擁有與診斷技術相關的重要專利的創新中心。由於意識和負擔能力的提高，印度市場正在快速成長。獲得預防性篩檢和診斷對於亞太地區客戶的購買行為至關重要。

FPNV定位矩陣

FPNV定位矩陣對於評估感染疾病體外診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對感染疾病診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.感染疾病體外診斷市場的市場規模與預測為何？

2.在感染疾病體外診斷市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.感染疾病體外診斷市場的技術趨勢和法規結構是什麼？

4.感染疾病體外診斷市場主要廠商的市場佔有率為何？

5.進入感染疾病體外診斷市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和週期性流行病的傳播增加
      • 增加用於診斷感染疾病的快速檢測套組的引入
      • 實施政府控制病毒性疾病的舉措
    • 抑制因素
      • 召回感染疾病體外診斷產品
    • 機會
      • 基因組學和蛋白​​質組學的進展
      • 加大研發投入，推出新的IVD產品
    • 任務
      • 感染疾病體外診斷套件准入限制
  • 市場區隔分析
    • 產品：對檢測傳染性病原體的先進試劑的需求不斷成長
    • 技術：擴大分子診斷技術的採用，以快速檢測和量化愛滋病毒和肝炎感染等病毒量
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章感染疾病體外診斷市場：依產品

  • 裝置
  • 試劑
  • 軟體

第7章感染疾病體外診斷市場：依技術分類

  • 免疫化學
  • 微生物學
  • 分子診斷

第8章感染疾病體外診斷市場（依適應症）

  • 念珠菌症
  • 披衣菌感染
  • 困難梭狀芽孢桿菌
  • 創新的
  • 胃腸炎
  • 淋病
  • 肝炎
  • HIV
  • HPV
  • MRSA
  • 呼吸道病毒
  • 鏈球菌
  • 結核病和抗藥性結核病
  • ＶＲＥ

第9章感染疾病體外診斷市場：依最終用戶分類

  • 學術研究所
  • 診斷實驗室
  • 醫院/診所

第10章 南北美洲感染疾病體外診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區感染疾病體外診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東、非洲感染疾病體外診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • 羅氏推出下一代 QPCR 系統，以改善臨床需求並應對分子診斷的公共衛生挑戰
    • Biocare Medical 宣布推出新型 IVD 抗原修復室 ARC，用於可靠、準確且一致的熱誘導表位修復 (HIER)
    • 推出免疫組織化學新試劑解決方案“Optimer-Fc”
    • DxLab 在烤麵包機大小的盒子中提供實驗室品質的感染疾病和有害病原體檢測

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-A339DAEFAD44

[189 Pages Report] The Infectious Diseases In-Vitro Diagnostics Market size was estimated at USD 49.06 billion in 2023 and expected to reach USD 52.51 billion in 2024, at a CAGR 7.22% to reach USD 79.95 billion by 2030.

The infectious diseases in-vitro diagnostics market comprises devices, consumables, and services used to detect and identify infectious diseases in human samples, such as blood, urine, throat swabs, and others. The applications of these diagnostics encompass a wide range of diseases, such as Human Immunodeficiency Virus (HIV), Hepatitis, Tuberculosis (TB), Sexually Transmitted Infections (STIs), Respiratory Infections, and others. These tests are crucial for early detection, disease surveillance, epidemiology, and management of infections. The growth of the infectious diseases IVD market is influenced by factors such as the increased prevalence of infectious diseases globally, growing awareness and education about the importance of early detection and prevention, and rising healthcare expenditures and investments in healthcare infrastructure. However, stringent regulatory environments, lack of infrastructure and trained personnel, and high cost of advanced technologies are significant barriers to the market growth. Furthermore, developing point-of-care testing kits for rapid and on-site diagnosis and integrating artificial intelligence and machine learning algorithms to improve diagnostic accuracy and predictive analytics offer significant growth opportunities for infectious diseases in-vitro diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 49.06 billion
Estimated Year [2024] USD 52.51 billion
Forecast Year [2030] USD 79.95 billion
CAGR (%) 7.22%

Product: Rising demand for advanced reagents for testing infectious pathogens

Infectious disease diagnostics require sophisticated and specialized instruments designed to detect the presence of pathogens in clinical samples. These instruments vary from simple point-of-care testing kits to complex laboratory equipment, including PCR machines, immunoassay analyzers, and next-generation sequencers. The need for instruments can vary by healthcare setting; high-throughput systems are preferred in reference laboratories for their efficiency and automation, while point-of-care settings demand portable and user-friendly instruments. Reagents are essential consumables in infectious disease diagnostics, consisting of the chemicals and biological materials used in tests to detect the presence of pathogen-specific markers. These include primers, probes, antibodies, and enzymes necessary for assays. The need for reagents is sustained by the volume of tests performed and the diversity of pathogens that can be tested. Hence, laboratories often prefer vendors who can provide various reagents compatible with multiple instrument platforms. The software segment in infectious disease diagnostics includes data analysis, interpretation software, and information management systems that are critical for the operational efficiency of diagnostics. Preferences in software are based on user-friendly interfaces, robust data management capabilities, interoperability with other hospital systems, and compliance with regulatory standards such as HIPAA.

Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections

Immunochemistry, or immunoassay, is a key technology in infectious disease diagnostics, using the immune response (antibodies, antigens) to detect and quantify specific biomarkers in a sample. It includes tests such as ELISA (enzyme-linked immunosorbent assay), lateral flow assays, and Western blotting. Microbiology remains a foundational method for identifying infectious diseases, often involving collecting samples to isolate and identify pathogens using biochemical and phenotypic analysis. Microbiology is essential for drug resistance testing and understanding the epidemiology of infections. It's preferred when information about the antibiotic susceptibility of pathogens is required, guiding targeted treatment. Molecular diagnostics involves analyzing nucleic acids to identify infectious agents with high sensitivity and specificity. Common technologies include polymerase chain reaction, reverse-transcription PCR, and next-generation sequencing.

Regional Insights

The Americas represents a significant portion of the infectious diseases in-vitro diagnostics market due to its advanced healthcare infrastructure, high prevalence of infectious diseases, and strong presence of leading market players. Recent trends include the adoption of Molecular Diagnostics (MDx), Point-of-Care (PoC) testing, and increased investment in personalized medicine. EU countries exhibit diverse healthcare systems and regulations but collectively show a strong demand for high-quality in-vitro diagnostics. EU customers value the precision and reliability of tests, combined with the need for compliance with stringent EU regulations. The Middle East and Africa region encompass various markets with varying degrees of development. In Middle Eastern countries, there is a significant demand for state-of-the-art healthcare solutions, including the latest in-vitro diagnostics. Investments in healthcare infrastructure are notable in the Gulf Cooperation Council (GCC) countries. Meanwhile, the African market needs cost-effective and robust testing due to challenges like infectious disease prevalence and limited access to healthcare. International initiatives often drive investment and innovation, focusing on expanding access and building local expertise in diagnostics.

The Asia Pacific region is rapidly growing in the infectious diseases in-vitro diagnostics market. China's vast population and increasing healthcare expenditures drive market growth, with strong government support for improving healthcare infrastructure. Japan, with its advanced technology, focuses on high-end, automated diagnostic solutions and is an innovation hub with significant patents in diagnostics technology. India's market is burgeoning due to rising awareness and affordability. Preventive screenings and accessibility to diagnostics have become pivotal in customer purchasing behavior across the Asia Pacific region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Diseases In-Vitro Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Diseases In-Vitro Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaSorin S.p.A, DX Lab Inc., Epitope Diagnostics, Inc., F. Hoffmann La-Roche Ltd., Genspeed Biotech GmbH, Grifols, S.A., Hologic, Inc., Illumina, Inc., InBios International, Inc., Koninklijke Philips N.V., Laboratory Corporation Of America Holdings, Merck KGaA, Meril Life Sciences Pvt. Ltd., OraSure Technologies, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., Trinity Biotech PLC, Uniogen Oy, and Vela Diagnostics.

Market Segmentation & Coverage

This research report categorizes the Infectious Diseases In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
    • Reagents
    • Software
  • Technology
    • Immunochemistry
    • Microbiology
    • Molecular Diagnostics
  • Indication
    • Candidiasis
    • Chlamydia
    • Clostridium difficile
    • CRE
    • Gastroenteritis
    • Gonorrhea
    • Hepatitis
    • HIV
    • HPV
    • MRSA
    • Respiratory Virus
    • Streptococcus
    • TB and Drug-resistant TB
    • VRE
  • End-user
    • Academic Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Diseases In-Vitro Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Diseases In-Vitro Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Infectious Diseases In-Vitro Diagnostics Market?

4. What is the market share of the leading vendors in the Infectious Diseases In-Vitro Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Infectious Diseases In-Vitro Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence and Periodic Outbreak of Infectious Diseases
      • 5.1.1.2. Rising Adoption of Rapid Test Kits for Diagnosis of Infectious Diseases
      • 5.1.1.3. Implementation of Government Initiatives to Curb Viral Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls of Infectious Disease In-vitro Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genomics and Proteomics
      • 5.1.3.2. Increasing Investments in R&D to Launch New IVD Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Accessibility of Infectious Diseases In-vitro Diagnostics Kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for advanced reagents for testing infectious pathogens
    • 5.2.2. Technology: Expanding adoption of molecular diagnostics technology to quickly detect and quantify viral load, such as in HIV or hepatitis infections
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents
  • 6.4. Software

7. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Immunochemistry
  • 7.3. Microbiology
  • 7.4. Molecular Diagnostics

8. Infectious Diseases In-Vitro Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Candidiasis
  • 8.3. Chlamydia
  • 8.4. Clostridium difficile
  • 8.5. CRE
  • 8.6. Gastroenteritis
  • 8.7. Gonorrhea
  • 8.8. Hepatitis
  • 8.9. HIV
  • 8.10. HPV
  • 8.11. MRSA
  • 8.12. Respiratory Virus
  • 8.13. Streptococcus
  • 8.14. TB and Drug-resistant TB
  • 8.15. VRE

9. Infectious Diseases In-Vitro Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Launches Next-Generation Qpcr System to Advance Clinical Needs In Molecular Diagnostics and Address Public Health Challenges
    • 13.3.2. Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)
    • 13.3.3. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
    • 13.3.4. DxLab Delivers Lab-Quality Detection of Infectious Diseases and Harmful Pathogens in a Toaster-Size Box

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CRE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GASTROENTERITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HPV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MRSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY RESPIRATORY VIRUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TB AND DRUG-RESISTANT TB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VRE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 148. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 166. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 167. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. MALAYSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 172. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 174. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. PHILIPPINES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. SINGAPORE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 188. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. TAIWAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 206. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 207. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. THAILAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 214. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 215. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. VIETNAM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 229. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 232. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 233. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. DENMARK INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. EGYPT INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 248. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 249. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. FINLAND INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 256. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 257. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 262. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 263. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 264. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 265. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 270. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 271. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. ISRAEL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 280. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 281. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)

TABLE 290